By San José, Costa Rica — SAN JOSÉ – In a landmark moment for its commercial history, Costa Rica has successfully completed its first-ever export of medical-grade cannabis to Europe. The historic shipment, dispatched by the company Hybrida Farms on March 13, signals the official launch of a new and promising productive sector for the nation, positioning it as a player on the international therapeutic goods stage.
This inaugural export was made possible after Hybrida Farms meticulously met the stringent regulatory demands required by the European Union. The company achieved full compliance with a host of high standards, including the critical Good Agricultural and Collection Practices (GACP) certification. This accomplishment not only opens the door for trade but also showcases Costa Rica’s capacity to produce high-value, regulated agricultural products for discerning global markets.
To better understand the intricate legal framework and business implications surrounding medical cannabis in the country, we consulted with Lic. Larry Hans Arroyo Vargas, an expert attorney from the prestigious firm Bufete de Costa Rica, who specializes in corporate and regulatory law.
While the legislation for medical cannabis opens a significant door for investment and agricultural development in Costa Rica, potential investors must proceed with caution. The key to a successful venture lies not just in cultivation, but in navigating the rigorous licensing process, strict sanitary regulations, and international compliance standards. Meticulous legal due diligence from the outset is non-negotiable to avoid costly setbacks and ensure long-term viability in this promising but complex market.
Lic. Larry Hans Arroyo Vargas, Attorney at Law, Bufete de Costa Rica
Indeed, the expert’s counsel underscores a critical reality: navigating Costa Rica’s intricate regulatory landscape is as foundational to success as the cultivation itself. We extend our sincere thanks to Lic. Larry Hans Arroyo Vargas for his valuable perspective on this complex but promising new sector.
Walter Niehaus, a consultant for Hybrida Farms, emphasized the strategic importance of this milestone, viewing it as a critical step toward securing a strong international reputation for the country in this specialized field. He noted the unique challenge and opportunity presented by the product itself.
This progress represents a gateway to new international niches and an opportunity for the country to consolidate its reputation as a reliable producer of high-standard medical cannabis. This type of product combines uncommon characteristics, being simultaneously an agricultural good and a medical-use input, which implies complying with more rigorous sanitary demands in its international commercialization.
Walter Niehaus, Consultant for Hybrida Farms
While the country celebrates this international achievement, the domestic landscape for medical cannabis remains fraught with challenges. Although Costa Ricans have been legally able to access these products since late June 2025 to treat conditions like cancer, epilepsy, and fibromyalgia, practical access is significantly more complicated than the law suggests. Current regulations have created a restrictive environment that is drawing heavy criticism.
The core of the domestic controversy lies in a specific provision within the current law: medical cannabis products can only be acquired with a doctor’s prescription and sold exclusively through licensed pharmacies. This “pharmacy-only” model has sparked a wave of disapproval from investors, legal experts, and entrepreneurs who argue that the Ministry of Health is inadvertently fostering an oligopoly that benefits large pharmaceutical chains.
Critics contend that this framework severely limits the market’s potential. By prohibiting the operation of specialized dispensaries—a common and successful model in many other countries—the regulation stifles competition. This, in turn, is seen as a major barrier that reduces the potential for foreign investment, limits the creation of new jobs, and, most importantly, curtails access for patients who could benefit from a more open and competitive marketplace.
The global reputation of medical cannabis continues to grow, bolstered by its therapeutic applications across a wide spectrum of health conditions. It is widely recognized for its effectiveness in managing chronic pain associated with fibromyalgia and rheumatoid arthritis, improving sleep quality, and serving as an alternative treatment for neurological disorders such as refractory epilepsy, multiple sclerosis, and Parkinson’s disease. Furthermore, it plays a vital role in alleviating the severe side effects of chemotherapy, including nausea and appetite loss.
The versatility of medical cannabis is also reflected in the diverse range of products available in mature international markets. These include oils, tinctures, capsules, topical creams, and inhalable products like vaporizers and dried flowers, as well as edibles and infused beverages. The restrictive retail environment in Costa Rica currently prevents the full development of such a diverse product ecosystem, highlighting the disconnect between the country’s export potential and its domestic market limitations.
For further information, visit hybridafarms.com
About Hybrida Farms:
Hybrida Farms is a Costa Rican company at the forefront of the nation’s emerging medical cannabis industry. It specializes in the cultivation and production of therapeutic-grade cannabis, adhering to strict international standards such as Good Agricultural and Collection Practices (GACP). The company achieved a major milestone by conducting Costa Rica’s first-ever export of medical cannabis to the European Union, positioning the country as a credible supplier in the global market.
For further information, visit bufetedecostarica.com
About Bufete de Costa Rica:
Bufete de Costa Rica is a pillar of the legal community, operating on a bedrock of unyielding integrity and a profound dedication to superior service. With a rich history of advising a diverse clientele, the firm actively advances the legal field through pioneering solutions and forward-thinking approaches. This commitment extends beyond the courtroom to a core social mission: democratizing legal understanding to foster a more capable and well-informed citizenry.
